- Home
- SNCY vs PHAT Comparison
SNCY vs PHAT Comparison
Compare SNCY & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | PHAT |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 894.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNCY | PHAT |
|---|---|---|
| Price | $16.17 | $9.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $19.50 | ★ $19.83 |
| AVG Volume (30 Days) | 666.7K | ★ 1.2M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,126,769,000.00 | $175,110,000.00 |
| Revenue This Year | $12.27 | $93.04 |
| Revenue Next Year | $7.51 | $58.91 |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | 4.74 | ★ 216.93 |
| 52 Week Low | $10.14 | $4.25 |
| 52 Week High | $22.29 | $18.31 |
Technical Indicators
Market Signals| Indicator | SNCY | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 31.78 |
| Support Level | $15.36 | N/A |
| Resistance Level | $17.93 | $12.83 |
| Average True Range (ATR) | 0.65 | 0.72 |
| MACD | 0.05 | -0.26 |
| Stochastic Oscillator | 49.16 | 2.57 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.